What Is Eloralintide?
Eloralintide (LY3841136) is a novel once-weekly, selective AMY1R amylin receptor agonist developed by Eli Lilly for the treatment of obesity. Unlike cagrilintide, which non-selectively activates amylin and calcitonin receptors, eloralintide demonstrates 11- to 12-fold selectivity for the human AMY1R receptor over CTR and AMY3R, a design choice believed to drive its markedly improved gastrointestinal tolerability while preserving robust weight-loss efficacy. In a 48-week Phase 2 trial (NCT06230523) in 263 adults with obesity, monotherapy produced dose-dependent mean body weight reductions of 9.5% to 20.1% versus 0.4% with placebo, with weight loss curves not yet plateauing at week 48. Eli Lilly announced plans to initiate Phase 3 monotherapy trials by year-end 2025, and is concurrently evaluating eloralintide in combination with tirzepatide in the ATTAIN Phase 2 program.
Mechanism of Action
Subcutaneous injection allows the lipidated, albumin-binding peptide to achieve sustained plasma exposure. Eloralintide selectively activates AMY1R in the brainstem area postrema and hypothalamus, driving satiety and reduced food intake while sparing CTR-mediated GI side effects.
Key Benefits
Once-weekly subcutaneous dosing supported by 13–15 day half-life. Up to 20.1% mean body weight loss at 48 weeks in Phase 2 with markedly improved GI tolerability versus non-selective amylin agonists. Potential combination partner for tirzepatide.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Briere, D.A., Coskun, T., Cabrera, O., et al., 2025, Molecular Metabolism - Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Billings, L.K., et al., 2025, The Lancet - Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
Eli Lilly and Company, 2025, Eli Lilly Investor Press Release - A Study of LY3841136 in Adult Participants With Obesity or Overweight (Phase 2 Monotherapy)
ClinicalTrials.gov, 2024, ClinicalTrials.gov - A Study of Eloralintide (LY3841136) Alone or in Combination With Tirzepatide in Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN)
ClinicalTrials.gov, 2024, ClinicalTrials.gov - A Single Ascending Dose Study of LY3841136 in Healthy Participants (Phase 1)
ClinicalTrials.gov, 2022, ClinicalTrials.gov - Long acting amylin receptor agonists and uses thereof
Eli Lilly and Company, 2022, United States Patent Application Publication - What to know about eloralintide
Eli Lilly and Company, 2025, Lilly.com Stories